Welcome to LookChem.com Sign In|Join Free
  • or
Primaquine diphosphate is an established antimalarial drug that belongs to the 8-aminoquinoline class. It is known for its ability to kill late-stage gametocytes and hypnozoites, making it effective in treating persistent liver forms of P. vivax or P. ovale infection. Additionally, its use has contributed to the discovery of glucose-6-phosphate (G6P) dehydrogenase deficiency, as it can induce hemolytic anemia in patients lacking the G6P-metabolizing enzyme.

63-45-6

Post Buying Request

63-45-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

63-45-6 Usage

Uses

Used in Antimalarial Applications:
Primaquine diphosphate is used as an antimalarial drug for its ability to eliminate late-stage gametocytes and hypnozoites, which are responsible for persistent liver forms of P. vivax or P. ovale infection.
Used in Acetylcholinesterase Inhibition:
Primaquine diphosphate is also used as an acetylcholinesterase inhibitor, which can help in the treatment of certain neurological disorders by increasing the levels of acetylcholine in the brain.
Used in Historical Research:
Primaquine diphosphate has played a significant role in the discovery of glucose-6-phosphate (G6P) dehydrogenase deficiency. Its use in treating malaria led to the identification of hemolytic anemia in patients lacking the G6P-metabolizing enzyme, contributing to a better understanding of this genetic condition.

Biological Activity

primaquine, an 8-aminoquinoline, is introduced as a curative antimalarial agent in 1950. since then, the drug has been applied extensively to against the exoerythrocytic stage of malaria. it is demonstrated tthat primaquine, by binding to nucleic acids, could therefore block protein synthesis, alter lipid synthesis and interact with biological membranes. [1]

Clinical Use

Treatment of malaria (Plasmodium vivax and Plasmodium ovale), in combination with chloroquine Treatment of Pneumocystis jiroveci pneumonia (PCP), in combination with clindamycin

in vitro

chicken embryo cells (cec) model were adopted to investigate the effect of primaquine on newcastle disease virus replication. it was found that virus-induced hemadsorption was inhibited by primaquine in a dose-dependent manner and was completely suppressed by primaquine 250 g/ml. viral ribonucleic acid (rna) synthesis was found to be suppressed when primaquine was added early in the virus replication cycle. whereas, when the drug was added late in the cycle, rna synthesis was stimulation. [1]

in vivo

primaquine liposomes were labelled by 99mtc and injected intravenously to swiss albino mice. after injection, the major accumulation organ of liposomes was liver followed by spleen, pancreas, lungs and the others. findings also suggested that primaquine could block the eradication of the parasites and prevent relapse by destruction of the exoerythrocytic liver stages. [2]

Drug interactions

Potentially hazardous interactions with other drugs Antimalarials: avoid concomitant use with artemether/lumefantrine.

Metabolism

Rapidly metabolised in the liver. Its major metabolite carboxyprimaquine accumulates in the plasma on repeated dosage but possesses less antimalarial activity than the parent compound. Little unchanged drug is excreted in the urine.

Purification Methods

It forms yellow crystals from 90% aqueous EtOH and is moderately soluble in H2O. The oxalate salt has m 182.5-185o (from 80% aqueous EtOH), and the free base is a viscous liquid b 165-170o/0.002mm, 175-177o/2mm. [Elderfield et al. J Am Chem Soc 68 1526 1964, Elderfield et al. J Am Chem Soc 77 4817 1955, Beilstein 22 III/IV 5817.]

references

[1]burdick jr and durand dp. primaquine diphosphate: inhibition of newcastle disease virus replication. antimicrob agents ch. 1974 oct 15; 6(4): 460-4.[2]aricat b, ozert ay, ercans mt and hincalt aa. characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. j. microencapsulation. 1995; 12(5): 469-85.[3]soto j, toledo j, rodriquez m, sanchez j, herrera r, padilla j and berman j. double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune colombian soldiers. clin infect dis. 1999 jul; 29: 199-201.

Check Digit Verification of cas no

The CAS Registry Mumber 63-45-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 63-45:
(4*6)+(3*3)+(2*4)+(1*5)=46
46 % 10 = 6
So 63-45-6 is a valid CAS Registry Number.
InChI:InChI=1/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)

63-45-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (P2940000)  Primaquine diphosphate  European Pharmacopoeia (EP) Reference Standard

  • 63-45-6

  • P2940000

  • 1,880.19CNY

  • Detail
  • USP

  • (1561507)  Primaquine phosphate  United States Pharmacopeia (USP) Reference Standard

  • 63-45-6

  • 1561507-200MG

  • 4,662.45CNY

  • Detail
  • Aldrich

  • (160393)  Primaquinebisphosphate  98%

  • 63-45-6

  • 160393-1G

  • 390.78CNY

  • Detail
  • Aldrich

  • (160393)  Primaquinebisphosphate  98%

  • 63-45-6

  • 160393-10G

  • 2,322.45CNY

  • Detail

63-45-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Primaquine bisphosphate

1.2 Other means of identification

Product number -
Other names 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine,phosphoric acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:63-45-6 SDS

63-45-6Synthetic route

Primaquine
90-34-6

Primaquine

primaquine diphosphate
63-45-6

primaquine diphosphate

Conditions
ConditionsYield
With phosphoric acid In diethyl ether Darkness;
4-methoxy-2-nitroaniline
96-96-8

4-methoxy-2-nitroaniline

primaquine diphosphate
63-45-6

primaquine diphosphate

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: arsenic(V) oxide; phosphoric acid / 1 h / 100 °C / Darkness
2: hydrogen / 2585.81 Torr / Darkness
3: triethylamine / 6 h / 150 °C / Darkness
4: hydrazine / ethanol / 72 h / Reflux; Darkness
5: phosphoric acid / diethyl ether / Darkness
View Scheme
6-methoxy-8-nitroquinoline
85-81-4

6-methoxy-8-nitroquinoline

primaquine diphosphate
63-45-6

primaquine diphosphate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: hydrogen / 2585.81 Torr / Darkness
2: triethylamine / 6 h / 150 °C / Darkness
3: hydrazine / ethanol / 72 h / Reflux; Darkness
4: phosphoric acid / diethyl ether / Darkness
View Scheme
6-methoxyquinolin-8-amine
90-52-8

6-methoxyquinolin-8-amine

primaquine diphosphate
63-45-6

primaquine diphosphate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: triethylamine / 6 h / 150 °C / Darkness
2: hydrazine / ethanol / 72 h / Reflux; Darkness
3: phosphoric acid / diethyl ether / Darkness
View Scheme
N-phthalolylprimaquine
83532-78-9

N-phthalolylprimaquine

primaquine diphosphate
63-45-6

primaquine diphosphate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrazine / ethanol / 72 h / Reflux; Darkness
2: phosphoric acid / diethyl ether / Darkness
View Scheme
Z-Lys(Boc)-OH
2389-60-8

Z-Lys(Boc)-OH

primaquine diphosphate
63-45-6

primaquine diphosphate

4'-N-(Nε-boc-N-Cbz-lysyl)primaquine

4'-N-(Nε-boc-N-Cbz-lysyl)primaquine

Conditions
ConditionsYield
With benzotriazol-1-ol; triethylamine; dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide 1.) 0 deg C, 4 h, 2.) RT, overnight;95%
2-chloro-4,6-dimethylpyrimidine-5-carboxylic acid ethyl ester
108381-23-3

2-chloro-4,6-dimethylpyrimidine-5-carboxylic acid ethyl ester

primaquine diphosphate
63-45-6

primaquine diphosphate

ethyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4,6-dimethylpyrimidin-5-carboxylate

ethyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4,6-dimethylpyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;95%
primaquine diphosphate
63-45-6

primaquine diphosphate

C15H19(2)H2N3O
1318851-87-4

C15H19(2)H2N3O

Conditions
ConditionsYield
With sulfuric acid; water-d2 at 95℃; for 8h; Temperature;95%
2-chloro-4-methyl-6-phenylpyrimidine-5-carboxylic acid ethyl ester
36746-07-3

2-chloro-4-methyl-6-phenylpyrimidine-5-carboxylic acid ethyl ester

primaquine diphosphate
63-45-6

primaquine diphosphate

ethyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-phenylpyrimidin-5-carboxylate

ethyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-phenylpyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;94%
primaquine diphosphate
63-45-6

primaquine diphosphate

acetic anhydride
108-24-7

acetic anhydride

N-acetyl-primaquine
77229-67-5

N-acetyl-primaquine

Conditions
ConditionsYield
In dichloromethane at 20℃; for 1h;92%
isopropyl 2-chloro-4-methyl-6-phenylpyrimidine-5-carboxylate
1448992-15-1

isopropyl 2-chloro-4-methyl-6-phenylpyrimidine-5-carboxylate

primaquine diphosphate
63-45-6

primaquine diphosphate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-phenylpyrimidin-5-carboxylate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-phenylpyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;92%
methyl 2-chloro-4,6-dimethylpyrimidine-5-carboxylate

methyl 2-chloro-4,6-dimethylpyrimidine-5-carboxylate

primaquine diphosphate
63-45-6

primaquine diphosphate

methyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4,6-dimethylpyrimidin-5-carboxylate

methyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4,6-dimethylpyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;92%
2-chloro-4-(4-fluorophenyl)-6-methylpyrimidine-5-carboxylic acid ethyl ester
1448992-18-4

2-chloro-4-(4-fluorophenyl)-6-methylpyrimidine-5-carboxylic acid ethyl ester

primaquine diphosphate
63-45-6

primaquine diphosphate

ethyl 4-(4-fluorophenyl)-2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methylpyrimidin-5-carboxylate

ethyl 4-(4-fluorophenyl)-2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methylpyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;91%
C15H14ClN3O4
1376766-60-7

C15H14ClN3O4

primaquine diphosphate
63-45-6

primaquine diphosphate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(4-nitrophenyl)pyrimidin-5-carboxylate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(4-nitrophenyl)pyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;91%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

primaquine diphosphate
63-45-6

primaquine diphosphate

tert-butyl (4-((6-methoxyquinolin-8-yl)amino)pentyl)carbamate

tert-butyl (4-((6-methoxyquinolin-8-yl)amino)pentyl)carbamate

Conditions
ConditionsYield
With triethylamine In dichloromethane at 25℃;91%
Ethyl 2-chloro-4-(4-methoxyphenyl)-6-methylpyrimidine-5-carboxylate

Ethyl 2-chloro-4-(4-methoxyphenyl)-6-methylpyrimidine-5-carboxylate

primaquine diphosphate
63-45-6

primaquine diphosphate

Ethyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(4-methoxyphenyl)pyrimidin-5-carboxylate

Ethyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(4-methoxyphenyl)pyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;90%
3,4-dibutoxy-3-cyclobutene-1,2-dione
2892-62-8

3,4-dibutoxy-3-cyclobutene-1,2-dione

primaquine diphosphate
63-45-6

primaquine diphosphate

C34H40N6O4
1487428-85-2

C34H40N6O4

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With triethylamine In methanol at 20℃; for 0.5h; Inert atmosphere;
Stage #2: 3,4-dibutoxy-3-cyclobutene-1,2-dione In methanol for 48h; Inert atmosphere; Reflux;
89%
C15H14ClN3O4
1376766-58-3

C15H14ClN3O4

primaquine diphosphate
63-45-6

primaquine diphosphate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(3-nitrophenyl)pyrimidin-5-carboxylate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(3-nitrophenyl)pyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;88%
2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-(diphenylmethyl)-4-methylpentanamide

2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-(diphenylmethyl)-4-methylpentanamide

primaquine diphosphate
63-45-6

primaquine diphosphate

N-(diphenylmethyl)-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)-amino]-4-methylpentanamide

N-(diphenylmethyl)-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)-amino]-4-methylpentanamide

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With sodium hydroxide In water pH=9 - 10;
Stage #2: 2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-(diphenylmethyl)-4-methylpentanamide In 1,4-dioxane at 20℃; Darkness;
87%
primaquine diphosphate
63-45-6

primaquine diphosphate

Primaquine
90-34-6

Primaquine

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃; for 2h; pH=10; Darkness;86%
With water; sodium hydroxide Heating;60%
Stage #1: primaquine diphosphate With triethylamine In dichloromethane for 0.5h; Cooling with ice;
Stage #2: In 2,2'-iminobis[ethanol]
C15H14ClN3O4
1376766-59-4

C15H14ClN3O4

primaquine diphosphate
63-45-6

primaquine diphosphate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(2-nitrophenyl)pyrimidin-5-carboxylate

isopropyl 2-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-methyl-4-(2-nitrophenyl)pyrimidin-5-carboxylate

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;85%
2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-[(4-chlorophenyl)(phenyl)methyl]-2-phenylacetamide

2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-[(4-chlorophenyl)(phenyl)methyl]-2-phenylacetamide

primaquine diphosphate
63-45-6

primaquine diphosphate

N-[(4-chlorophenyl)(phenyl)methyl]-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]-2-phenylacetamide

N-[(4-chlorophenyl)(phenyl)methyl]-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]-2-phenylacetamide

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With sodium hydroxide In water pH=9 - 10;
Stage #2: 2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-[(4-chlorophenyl)(phenyl)methyl]-2-phenylacetamide In 1,4-dioxane at 20℃; Darkness;
85%
(N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)-1H-benzo[d][1,2,3]triazole-1-carboxamide)
1042740-40-8

(N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)-1H-benzo[d][1,2,3]triazole-1-carboxamide)

primaquine diphosphate
63-45-6

primaquine diphosphate

1,3-bis(4-((6-methoxyquinolin-8-yl)amino)pentyl)urea
1267807-38-4

1,3-bis(4-((6-methoxyquinolin-8-yl)amino)pentyl)urea

Conditions
ConditionsYield
With sodium dithionite; triethylamine In dichloromethane at 65℃; Microwave irradiation; Darkness;84%
3,4-dibutoxy-3-cyclobutene-1,2-dione
2892-62-8

3,4-dibutoxy-3-cyclobutene-1,2-dione

primaquine diphosphate
63-45-6

primaquine diphosphate

C23H29N3O4
1487428-84-1

C23H29N3O4

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With triethylamine In methanol at 20℃; for 0.5h; Inert atmosphere;
Stage #2: 3,4-dibutoxy-3-cyclobutene-1,2-dione In methanol for 48h; Inert atmosphere; Reflux;
82%
primaquine diphosphate
63-45-6

primaquine diphosphate

cyclohexanone
108-94-1

cyclohexanone

mercaptoacetic acid
68-11-1

mercaptoacetic acid

4-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}-1-thia-4-azaspiro[4.5]decan-3-one
1356475-81-4

4-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}-1-thia-4-azaspiro[4.5]decan-3-one

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In toluene at 110℃; for 3h;80%
primaquine diphosphate
63-45-6

primaquine diphosphate

3,4-dimethoxy-3-cyclobutene-1,2-dione
5222-73-1

3,4-dimethoxy-3-cyclobutene-1,2-dione

3-methoxy-4-({4-[(6-methoxyquinolin-8-yl)amino]pentyl}amino)cyclobut-3-ene-1,2-dione

3-methoxy-4-({4-[(6-methoxyquinolin-8-yl)amino]pentyl}amino)cyclobut-3-ene-1,2-dione

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With triethylamine In methanol at 20℃; for 0.5h; Inert atmosphere;
Stage #2: 3,4-dimethoxy-3-cyclobutene-1,2-dione In methanol for 12h; Inert atmosphere; Reflux;
79%
octane-1,8-dioic acid
505-48-6

octane-1,8-dioic acid

primaquine diphosphate
63-45-6

primaquine diphosphate

N,N’-bis({4-[(6-methoxyquinolin-8-yl)amino]pentyl})octanediamide

N,N’-bis({4-[(6-methoxyquinolin-8-yl)amino]pentyl})octanediamide

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With triethylamine In dichloromethane
Stage #2: octane-1,8-dioic acid With N-ethyl-N,N-diisopropylamine; HATU In dichloromethane at 20℃; for 24h;
78%
succinic acid
110-15-6

succinic acid

primaquine diphosphate
63-45-6

primaquine diphosphate

N,N'-bis({4-[(6-methoxyquinolin-8-yl)amino]pentyl})butanediamide

N,N'-bis({4-[(6-methoxyquinolin-8-yl)amino]pentyl})butanediamide

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With triethylamine In dichloromethane
Stage #2: succinic acid With N-ethyl-N,N-diisopropylamine; HATU In dichloromethane at 20℃; for 24h;
77%
C35H44N6O13

C35H44N6O13

primaquine diphosphate
63-45-6

primaquine diphosphate

C44H60N8O11

C44H60N8O11

Conditions
ConditionsYield
With sodium hydroxide In N,N-dimethyl-formamide76%
1,5-pentanedioic acid
110-94-1

1,5-pentanedioic acid

primaquine diphosphate
63-45-6

primaquine diphosphate

N,N’-bis({4-[(6-methoxyquinolin-8-yl)amino]pentyl})pentanediamide

N,N’-bis({4-[(6-methoxyquinolin-8-yl)amino]pentyl})pentanediamide

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With triethylamine In dichloromethane
Stage #2: 1,5-pentanedioic acid With N-ethyl-N,N-diisopropylamine; HATU In dichloromethane at 20℃; for 24h;
73%
primaquine diphosphate
63-45-6

primaquine diphosphate

p-[(10-dihydroartemisininoxy)methyl]benzoic acid

p-[(10-dihydroartemisininoxy)methyl]benzoic acid

C38H49N3O7
1519728-36-9

C38H49N3O7

Conditions
ConditionsYield
Stage #1: p-[(10-dihydroartemisininoxy)methyl]benzoic acid With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; triethylamine In dichloromethane at 0℃; for 1h;
Stage #2: primaquine diphosphate With triethylamine In dichloromethane at 0 - 20℃;
72%
primaquine diphosphate
63-45-6

primaquine diphosphate

8-amino-6-hydroxyquinoline dihydrobromide

8-amino-6-hydroxyquinoline dihydrobromide

Conditions
ConditionsYield
With hydrogen bromide for 48h; Heating;71%
2-(1H-benzo[d][1,2,3]triazole-1-carbonyl)-N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazinecarboxamide

2-(1H-benzo[d][1,2,3]triazole-1-carbonyl)-N-(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazinecarboxamide

primaquine diphosphate
63-45-6

primaquine diphosphate

N,N-bis(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazine-1,2-dicarboxamide

N,N-bis(4-((6-methoxyquinolin-8-yl)amino)pentyl)hydrazine-1,2-dicarboxamide

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane; diethyl ether68%
dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1

dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1"-cyclohexane]-3"-yl 4-nitrophenylcarbonate

primaquine diphosphate
63-45-6

primaquine diphosphate

dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1

dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1"-cyclohexane]-3"-yl N-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 18h;68%
2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-(4-bromophenyl)-2-(4-chlorophenyl)acetamide

2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-(4-bromophenyl)-2-(4-chlorophenyl)acetamide

primaquine diphosphate
63-45-6

primaquine diphosphate

N-(4-bromophenyl)-2-(4-chlorophenyl)-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]acetamide

N-(4-bromophenyl)-2-(4-chlorophenyl)-2-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]acetamide

Conditions
ConditionsYield
Stage #1: primaquine diphosphate With sodium hydroxide In water pH=9 - 10;
Stage #2: 2-[(1H-1,2,3-benzotriazole-1-carbonyl)amino]-N-(4-bromophenyl)-2-(4-chlorophenyl)acetamide In 1,4-dioxane at 20℃; Darkness;
67%

63-45-6Relevant academic research and scientific papers

Preparation method of primaquine phosphate

-

Paragraph 0055-0072, (2021/08/14)

The invention discloses a preparation method of primaquine phosphate, which is characterized by comprising the following steps of: adding a secondary condensate, ethanol and hydrazine hydrate into a reaction container, introducing nitrogen for protection, stirring in a dark place, heating to 78-80 DEG C, carrying out reflux reaction until the reaction is complete, evaporating ethanol under normal pressure until the internal temperature is increased to 92-95 DEG C, adding water, stirring, heating to 58-62 DEG C to enable no solid to suspend, cooling to 40-50 DEG C, dropwise adding a sodium hydroxide solution with the mass concentration of 25-30% while stirring to enable the pH to be 13-14, stirring, adding methylbenzene, stirring, standing for layering, adding water into an organic phase for washing, then decolorizing with activated carbon, filtering and concentrating to obtain free primaquine oil, and adding dichloroethane for crystallization to obtain free primaquine. By adjusting process parameters (such as reaction temperature, time, light shielding, nitrogen protection and charging sequence) of each step, a dichloroethane crystallization process of free primaquine is added, the purity of a finished product is greater than 99.5%, the content of a single impurity is less than 0.2%, and the yield is high.

Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents

Azad, Chandra S.,Saxena, Mridula,Siddiqui, Arif J.,Bhardwaj, Jyoti,Puri, Sunil K.,Dutta, Guru P.,Anand, Nitya,Saxena, Anil K.

, p. 254 - 261 (2017/07/13)

Primaquine (PQ) is the only drug used to prevent relapse of malaria due to P. vivax and P. ovale, by eradicating the dormant liver form of the parasite (hypnozoites). The side-effects associated with PQ limits is uses in treatment of malaria. To overcome the premature oxidative deamination and to increase the life span of drug in the biological system, the novel glyco-conjugates of PQ were synthesized by coupling of primaquine with hexoses in phosphate buffer. The saccharide part of the hybrid molecules thought to direct the drug to the liver, where hypnozoites resides. All the synthesized compounds were fully characterized and evaluated for their radical curative activities. The three compounds viz glucoside (15a), galactoside (15b) and mannoside (15c) with high activity were tested for their activity in rhesus monkeys where the most active compound 15b showed twofold activity (100% radical curative activity at 1.92?mmol/kg) than the standard drug PQ diphosphate (3.861?mmol/kg). It is proposed that results from these studies may be advantageous to develop a new potent tissue schizonticide antimalarial compound.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 63-45-6